Square vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Q2 2025: Gross profit $2.5B (+14% YoY), adjusted operating income $550M (+38% YoY); raised full year guidance to $10.17B gross profit (+14% YoY); mid-market merchants 45% of GPV with 20% annual growth
About
Square was founded in 2009 by Jack Dorsey and Jim McKelvey to enable any business owner to accept card payments with a smartphone and simple dongle, democratizing point-of-sale infrastructure that had been gated behind expensive hardware and merchant account applications. The founding insight — that payment acceptance was a software problem, not a financial services gatekeeping function — transformed the merchant services market. Square's core technology evolved from a card reader into a full commerce operating system covering payments, POS software, inventory, scheduling, and loyalty.\n\nSquare's platform serves businesses from sole-proprietor food stalls to multi-location retailers with Square POS, Square Online for e-commerce, Square Payroll, Square Loans, Square Marketing, and hardware including terminals and kitchen display systems. It is designed to provide enterprise-grade commerce functionality without enterprise-grade implementation complexity. Square is a subsidiary of Block, Inc. — renamed from Square, Inc. in 2021 — alongside Cash App and Afterpay.\n\nSquare generated $2.5 billion in gross profit in Q2 2025, up 14% year-over-year, with Block raising full-year 2025 guidance to $10.17 billion. It competes with Shopify, Toast, and Stripe, differentiating through hardware-to-software integration, SMB focus, and embedded financial services including Square Loans and Afterpay. Its combination of payment processing scale, business management software, and embedded financial products positions it as the most comprehensive commerce platform for US SMBs.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.